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Abstract
Currently, cancer is one of the major health problems of the human population 
and prominent cause of death. Thiazole ring has demonstrated many pharmaco-
logical activities including anticancer. This scaffold has been found alone or incor-
porated into the diversity of therapeutic active agents such as tiazofurin, dasatinib, 
and bleomycin, which are well-known antineoplastic drugs. Recently, most of 
the compounds isolated from natural sources containing thiazole moiety exhibit 
notable cytotoxicities and present antitumor potential. In this context, several 
structural changes have been made in the original structure, such as the incorpora-
tion of different substituents or the fusion with other carbo- and heterocycles, in 
order to increase the antitumoral potency. Related to mechanism of action of these 
derivatives, some of them act through kinase modulation, polymerization inhibi-
tion of microtubule, pro-matrix metalloproteinase activation, signal transducer 
activation of transcription 3, histone deacetylase inhibition, etc.
Keywords: cancer, thiazole, MDM2 inhibitors, mechanism of action,  
metal complexes, peptides, sulfur
1. Introduction
Cancer is a generic term, which encompasses a wide group of diseases character-
ized essentially by an uncontrolled growth and propagation of cells with errors in 
the division mechanisms known as cell cycle. Cancer constitutes a major public 
health problem worldwide, since it is the second leading cause of death globally, 
with 9.6 million deaths estimated in 2018 [1]. Due to the limitations and side effects 
associated with available cancer treatments nowadays, it is an urgent challenge for 
medicinal researchers to develop more safe and selective anticancer drugs.
Among the design strategies in drug discovery, special attention has been paid 
to molecules containing sulfur heterocycles in their structures. Several studies have 
been carried out with plenty of sulfur heterocycles, including thiophene, thione, 
benzothiophene, and thiazine, towards different pathologies.
Thiazole ring is present in several anticancer drugs, such as bleomycin, sulfathi-
azole, thiazofurine, and dasatinib, and its derivatives present excellent pharmaco-
logical profiles, making this skeleton an ideal candidate to develop more potent and 
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safer drugs, especially in cancer. Herein, an extensive revision of the most relevant 
research published in the past 5 years is gathered.
2. Thiazole rings decorated with different fragments
2.1 Thiazole derivatives with in vitro efficacy
Aminothiazoles: Aminothiazoles have been widely used in drug discovery research 
due to its biological properties. Commercial drugs, such as famotidine, sudoxicam, or 
cefdinir, contain an aminothiazole core in their structures (Figure 1) [2].
Aminothiazole scaffold can be modified by derivatization of the amino group at 
position 2 of the thiazole ring. Rostom et al. [3] reported a study based on structural 
modifications including azomethine, N-formyl, N-acyl, sulfonamide, ureido, and 
thioureido functionalities. Nine derivatives were evaluated by the NCI in vitro 
screening panel assay, displaying most of them a promising antitumor activity 
against particular cell lines.
Sun et al. [4] synthesized a series of N,4-diaryl-1,3-thiazole-2-amines containing 
three aromatic rings with an amino linker. Compound 1 (Figure 2) was the most 
cytotoxic agent with IC50 values at the submicromolar level. A further biological 
evaluation showed that this compound inhibited polymerization and disrupted 
tubulin microtubule dynamics in a similar way to the natural product combretastatin 
A-4, besides effectively inducing SGC-7901 cell cycle arrest at the G2/M phase.
In other study, a series of tri-substituted aminothiazoles were designed by 
Lu et al. [5] in order to obtain new antitumoral agents. Compound 2 (Figure 2) 
displayed a EC50 value of 0.11 μM in hepatocellular carcinoma along with a selectiv-
ity towards nontumoral cells greater than 450 times.
A dysregulation of sirtuin 2 (Sirt2) plays an important role in the pathogenesis 
of cancer, among other diseases. Schiedel et al. [6] designed a series of novel 
aminothiazole derivatives with the aim of establishing a well-defined SAR model 
of sirtuin ligands. These thiazole-bearing compounds behaved as selective human 
sirtuins (hSirt2) inhibitors.
Chalcones: Chalcones are naturally biarylpropenones, which are classified as 
a subgroup of flavonoids with a broad spectrum of biological activities, including 
antimicrobial, anti-inflammatory, and anticancer properties [7].
A series of 4-amino-5-cinnamoylthiazoles as chalcone-like structures were 
synthesized and evaluated as antitumor agents, showing most of them significant 
cytotoxic activity against MCF-7, HepG2, and SW480 cell lines [8]. The most prom-
ising analog, compound 3 (Figure 2), revealed that it could prevent the prolifera-
tion of HepG2 cells by blocking cell cycle at the G2 phase and by inducing apoptosis.
Coumarins: Another strategy of design is the incorporation of a coumarin 
moiety in molecules containing thiazole. Many coumarin-bearing compounds are 
reported to have significant therapeutic potential, including anticancer activity 
Figure 1. 
Some aminothiazole as commercial drugs.
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through different mechanisms. Jashari et al. [9] reported the synthesis of new 
derivatives by combining this coumarin core with different heterocycles. The results 
showed that the compounds containing thiazoles in the structure had the most 
promising activity against the cancer cell lines tested.
This strategy can be complementary with the inclusion of other structures with 
recognized biological activities. A series of indole-incorporated thiazolylcouma-
rins were synthesized and evaluated against a wide range of tumor cell lines [10]. 
Among the tested compounds, structure 4 (Figure 2) exhibited a broad spectrum 
of growth inhibition activity with average GI50 values of 1.18–2.44 μM against nine 
cell lines.
Ayati et al. [11] also reported the synthesis of a series of new coumarin-containing 
compounds developed from the chalcone-like cinnamoylthiazoles mentioned above. 
Biological evaluations on the most cytotoxic compound 5 (Figure 2) against MCF-7 
cells revealed the induction of apoptosis and blockage of the cell cycle distribution at 
the G1-phase.
2.2 Thiazole derivatives with in vivo efficacy
For the past 5 years, few examples of scaffolds bearing a thiazole ring have been 
reported with potent efficacy in xenograft models of various types of cancer. Figure 3 
encompasses the most relevant examples gathered in the literature that are going to be 
discussed herein.
Attending to their structure, the thiazole analogs can be grouped as follows.
Diaminothiazoles: In 2015, several diaminothiazole derivatives were evaluated 
in vitro against wild-type and resistant colon, breast, and uterine cancer cells lines. 
All of them showed potent activity in all cell lines with IC50 values in the nanomolar 
range. Among them, DAT1 (4-amino-5-benzoyl-2-(4-methoxyphenylamino)thia-
zole) (Figure 3) also demonstrated in vivo tumor growth inhibition of around 60% 
in a taxol-resistant colon cancer model at a dose of 20 mg/kg [12]. More recently, 
DAT1 has also demonstrated its capacity to induce apoptosis both in vitro and in vivo 
against colon cancer models with mutated p53 through ERK-mediated upregulation 
of death receptor 5 (DR5) [13]. All these findings have placed DAT1 as a candidate 
to be tested in clinical trials.
(Thiazole-2-yl)hydrazones: Di Martile et al. reported that a novel pCAF and 
GCN5 histone deacetylase inhibitor, named CPTH6 (3-methylcyclopentylidene- 
[4-(4′-chlorophenyl)thiazol-2-yl] hydrazone) (Figure 3), was able to reduce tumor 
growth in a spheroid patient-derived lung cancer stem cells (LCSCs) xenograft model 
Figure 2. 
Thiazole derivatives as potential antitumor agents.
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accompanied by apoptosis induction and inhibition of α-tubulin acetylation [14]. 
Likewise, two 2-pyridyl-2,3-thiazole derivatives, TP-07 and TAP-07 (Figure 3), pos-
sess cytotoxic activity towards several cancer cell lines without antiproliferative effects 
to normal cells (IC50 > 30 μM) along with in vivo efficacy against a hepatocellular 
xenograft cancer model [15]. Thus, both compounds achieved 47% and 73% tumor 
mass reduction, respectively [15].
Spiroimidazothiazolidines: This class of compounds has demonstrated to be 
potent inhibitors of the Murine Double Minute-2 (MDM2)-p53 interaction, which 
ultimately leads to induction of apoptosis. Two analogs withstand in this class of 
compounds: a) ISA27 (Figure 3), which not only presented tumor growth inhibi-
tion in vivo alone in a glioblastoma xenograft model but also a synergistic effect 
with temozolomide, a first-line treatment drug against brain cancers [16], and  
b) SM13 (Figure 3), an analog that reduced tumor growth in a human thyroid 
cancer xenograft model in the absence of p53 transcriptional activity [17].
Piperidinone analogs: Based on previous morpholine and piperidone MDM2 
inhibitors, Gonzalez et al. introduced a thiazole ring decorated with a carboxylic 
acid over the piperidone scaffold. The resulting hit compound, termed AM-6761 
(Figure 3), maintained the MDM2 inhibition efficacy and presented an ED50 value 
of 11 mg/kg in SJSA-1 osteosarcoma xenograft model [18].
Oridonin derivatives: Oridonin is a complex ent-kaurane diterpenoid 
isolated from the traditional Chinese herb Isodon rubescens, with well-known 
cytotoxic activity against various human cancers. In 2013, Ding et al. designed 
a series of novel nitrogen-enriched oridonin derivatives with thiazole-fused 
A-ring. The hit compound, CYD0618 (Figure 3), induced a threefold shrinkage 
of the tumor volume in a triple-negative breast cancer MDA-MB-231 xenograft 
model at a dose of 5 mg/kg, showing much higher efficacy than parent oridonin 
[19]. Later, Zhou et al. reported another oridonin analog, CYD-6-17 (Figure 3),  
which significantly inhibited renal cell carcinoma tumor growth in vivo by 
targeting 3-phosphoinositide-dependent protein kinase 1 (PDPK1) and its 
downstream pathways [20].
Figure 3. 
Representative scaffolds containing thiazole ring with proven in vivo efficacy towards several cancer xenograft 
models.
5Thiazole Moiety: An Interesting Scaffold for Developing New Antitumoral Compounds
DOI: http://dx.doi.org/10.5772/intechopen.82741
3. Fused thiazole rings decorated with different fragments
Benzothiazoles: In the last few years, benzothiazoles have attracted consider-
able interest due to their broad spectrum of pharmacological activities, such as 
antitubercular, antimicrobial, analgesic, and antitumor properties [21].
This moiety can be functionalized with several structural modifications. Novel 
methylsulfonyl benzothiazoles were synthetized and evaluated against HeLA cell line, 
with compounds 6 and 7 (Figure 4) showing GI50 values of 0.1 μM or below [22].
Xie et al. [23] reported a new series of benzothiazole derivatives, with in vitro 
efficacy against HCT116, MCF-7, U87 MG, and A549 cell lines. Compound 8 
(Figure 4) was proved to retain the antiproliferative activity and the inhibitory 
activity against PI3K (phosphoinositide 3-kinase) and mTORC1 (mammalian target 
of rapamycin), which are abnormally active in many tumor cells.
Benzothiazole derivatives bearing pyrimidine moiety were synthetized and 
evaluated for anticancer activity against MCF-7, A549, and A375 cancer cell lines, 
with significant antitumor activity. A further study of the most promising com-
pounds indicated an effect on the expression of proteins that cause abnormal cell 
proliferation, such as ERK1/2, NF-kB, and survivin [24].
This moiety can also be used in the design of new molecules with a chalcone-
like structure, as it has been mentioned before. Imidazole bearing benzothiazoles 
were synthetized by Sultana et al. [25] and evaluated against several cancer cell 
lines. Compounds 9 and 10 (Figure 4) exhibited good cytotoxicity against human 
breast cancer (MDA MB-231) with IC50 values of 1.3 and 1.2 μM, respectively. These 
compounds were revealed to induce cell cycle arrest in G2/M phase and to inhibit 
microtubule assembly.
Imidazoles: Imidazole-based compounds have achieved great progress in medici-
nal chemistry, since they have showed anticancer, antifungal, antibacterial, and anti-
parasitic activities, among others [26]. Their use as heterocycles merged with thiazole 
has attracted great attention in the last years [27, 28] due to its therapeutic properties.
A series of imidazo[2,1-b]thiazole derivatives were evaluated against different 
tumor cell lines, showing that compounds 11 and 12 (Figure 4) had a significant 
cytotoxic activity against A549 with IC50 values of 0.92 and 0.78 μM, respectively. 
These derivatives had proven to induce cell cycle arrest in G2/M phase and apopto-
sis in this cell line [29]. Ali et al. [30] synthesized a series of imidazo[2,1-b]thiazoles 
decorated with pyrazoles that turned out to be promising leads to further develop.
Figure 4. 
Some thiazole-fused compounds with antitumor activity.
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Due to the pharmacological properties of the imidazo[2,1-b]thiazole derivatives 
and coumarin compounds already mentioned, it has been reported a design that 
embodied both the active pharmacophores in a single molecule in order to evaluate 
their synergic activity against a series of tumor cell lines [31], showing some of 
them prominent cytotoxic activity.
Kamal et al. [32] also designed a novel series of imidazole merged with thiazole 
as chalcone-like derivatives and evaluated their cytotoxic activity against MCF-7, 
A549, HeLA, DU-145, and HT-29 cell lines. Among the compounds tested, struc-
ture 13 (Figure 4) with a pyridyl ring was the most active. This compound also 
disrupted microtubule dynamics, induced cell cycle arrest in G2/M phase and 
ultimately trigger apoptosis.
Pyrimidines: Compounds with fused rings can also be formed by merging other 
heterocyclic moieties with thiazole core. Li et al. [33] reported a novel series of 
thiazolo[5,4-d]pyrimidine derivatives, which were evaluated against three cancer 
cell lines. Compound 14 (Figure 4) showed the most potent antiproliferative activ-
ity with good selectivity when compared to normal cells (IC50 values of 1.03 μM 
against MGC803 and 38.95 μM against GES-1). Biological studies indicated that 
this compound could inhibit the cell colony formation and migration by inducing 
apoptosis on MGC803 cells.
A series of thiazolo[3,2-a]pyrimidines were synthetized and evaluated in the 
NCI-60 cell lines panel assay, achieving significant cytotoxicity against some of the 
cell lines tested [34].
4. Miscellaneous structures bearing thiazole ring
Diazepines: Heterocyclic compounds 1,4-diazepines are considered an interest-
ing moiety in drug research due to their broad range of pharmacological activities, 
including antibacterial, anti-HIV, anticonvulsant, and anticancer [35]. Ramírez 
et al. designed a series of novel thiazole-based compounds by fusing this structure 
with pyrimidine, which has also showed biological properties. The results indicated 
that some compounds showed promising antitumoral activity, with GI50 values 
below 2 μM against NCI’s in vitro cell line screening [35].
Pyrazoline: Another heterocyclic structure used in combination with thiazole 
moiety is the pyrazoline ring. New thiazolyl-pyrazoline derivatives were synthe-
tized, and their cytotoxicity was evaluated against A549 human lung adenocarci-
noma and NIH/3 T3 mouse embryonic fibroblast cells, presenting in some cases 
similar IC50 values to cisplatin [36].
Curcumins: Bayomi et al. [37] synthetized and evaluated a series of new 
curcumin analogs bearing thiazole as antitumoral and antioxidant agents, showing 
similar behavior than that of cisplatin and ascorbic acid, respectively.
Thiazolines: Thiazolines are the reduced form of thiazole and also have 
attracted interest in drug research due to its biological activity. Altintop et al. [38] 
evaluated a series of new thiazoline-based derivatives bearing a hydrazone moiety. 
The results showed that some of the compounds were potent inhibitors of DNA 
synthesis against C6 tumor cells.
5. Thiazole and metal complexes
There is a great variability of transition metals that in combination with dif-
ferent ligands have been reported as antitumoral agents acting through different 
mechanisms. The literature revealed the considerable interest in the thiazole 
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pharmacophore alone [39], fused to other rings [40], or incorporated into different 
structures [41] for cancer therapy.
On the other hand, among the most effective and well-studied class of chemo-
therapeutic agents are the platinum-based drugs, which comprise cisplatin, carbopla-
tin, and oxaliplatin. Given the clinical success of the platinum-based drugs, extensive 
research efforts have been made to develop alternative metal ions, that is, ruthenium, 
copper, zinc, and nickel, with antitumor activity.
Copper complexes: Copper complexes have attracted a vast interest due to 
their bioavailability, increased uptake in cancerous tissues, role in angiogenesis 
and photophysical properties, among others. The most common types of copper 
complexes are those incorporating 1,10-phenanthroline (phen) ligands. Planarity of 
the intercalative ligand is crucial in the binding of these complexes with DNA. The 
complexes containing nonplanar ligands favored groove binding [42].
Besides, Shakir et al. [43] have reported several Cu (II) complexes derived from 
benzothiazole and thiazole, which showed greater antioxidant and anticancer 
activities than the corresponding free ligands in various cell lines.
Studies carried out with several Cu (II) complexes with 2,2,6′,2′′-terpyridines 
revealed that these complexes are able to promote the generation of reactive oxy-
gen species (ROS) in the presence of mild reducing agents. This feature has been 
exploited to oxidatively break the DNA strands, hence inhibiting the prolifera-
tion of tumor cells. In this context, the replacement of two pyridine rings by two 
thiazole nuclei (compound 15 in Figure 5) also achieved efficient DNA cleavage in 
several tumor cell lines [44]. Later, Czerwinska et al. corroborated an increase in 
the antiproliferative effect of these complexes against ovarian carcinoma cells by 
apoptosis [45].
In addition, the copper complexes have been recognized as promising drugs for 
metastatic tumors. For example, copper complexes of pyrrolidine dithiocarbamate 
(Cu(PDTC)2) possessed potent anticancer activity on cisplatin-resistant neuroblas-
toma cells. Additionally, two copper thiosemicarbazone complexes showed similar 
effect on cisplatin-resistant neuroblastoma cells and prostate cancer. Xie et al. [46] 
reported the synthesis and antitumoral activity of two copper complexes of (4R)-
2-thioxo-4-thiazolidinecarboxylic acid (TTDC) and 3-rhodaninepropionic acid 
(RDPA) against prostate cancer, presenting both of them variable potency, likely 
Figure 5. 
Some thiazole-metal complexes with antitumor activity.
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related to different functional groups on TTDC and RDPA ligands. Owing to the 
presence of sulfur and amino groups in CuTTDC and CuRDPA, these complexes 
had emerged as ligands to attach to delivery vehicles, such as peptides or monoclo-
nal antibodies for targeted delivery.
It is notably that a number of copper (II) complexes have been shown to pres-
ent antitumor activity, through inhibition of human topoisomerase IIα. Recently, 
Sandhaus et al. [47] have identified a new complex (compound 16 in Figure 5) with 
potent antiproliferative activity towards colon cancer cell lines (HTC-116, Caco-2, 
and HT-29) and aggressive breast cancer cell lines (HCC 1500, HCC 70, HCC 1806, 
and HCC 1395).
Ruthenium complexes: Currently, ruthenium complexes are found to be a 
promising alternative for platinum because of favorable properties as anticancer 
drugs. Among the ligands, 2,6-di(thiazol-2-yl)pyridine combined with phenantro-
lines have demonstrated to act as DNA intercalative agents along with topoisom-
erase I and IIα inhibitors (compound 17 in Figure 5) [48]. The assays with other 
ligands, such as 1,3-thiazolidine-2-thione, with 1,4-bis(diphenylphosphino)butane 
or 2,2′-bipyridine, displayed strong cytotoxicity against breast and prostate cancer 
cell lines [49].
Platinum and palladium complexes: Platinum and palladium have similar 
chemical properties and modes of coordination, but the palladium compounds 
are more labile from a thermodynamic and a kinetic point of view with relation to 
platinum derivatives.
Rubino and co-workers [50] have reported two new mono-Pt(II) and binuclear 
chloro-bridged Pd(II) complexes with 2,2′-dithiobis(benzothiazole) as ligand. Only 
platinum derivative has emerged as an effective inductor of apoptotic death on 
HepG2 and MCF-7 cells and caused cell cycle arrest at G0/G1 phase while palladium 
was inactive. On the other hand, the inclusion of 2-(4-substituted)benzothiazoles 
(compound 18 in Figure 5) as ligands resulted in potent cytotoxic agents through 
tubulin polymerization in A549 and HeLa cell lines [51].
In addition, thiazolidinone-derived complexes, specifically with (Z)-2-((E)-(1-
(pyridin-2-yl)ethylidene)hydrazono)thiazolidin-4-one, were markedly cytotoxic 
to MCF-7, HepG2, and NCI-H460 and presented better profile than cisplatin [52]. 
Other relevant strategy is the combination with scaffold with proven anticancer 
activity. In this context, the coumarin-thiazole analogs complexed with platinum 
or palladium showed that the Pd complex had higher antitumor effects than its Pt 
analogs in several cancer cell lines [53].
Other metal complexes and applications: Manganese is a metal that plays a 
critical role in cell development, and it is required for mitochondrial function. As 
novelty, Islam et al. [54] have described a new Mn-EDTA complex (compound 19 
in Figure 5) incorporating a benzothiazole that has been investigated as potential 
agents for diagnosis of liver cancer by magnetic resonance.
Cobalt (II) complexes are one of the most studied, and they have been reported 
as cytotoxic agents in vitro against breast cancer cell lines [55]. However, the cobalt 
(III) complexes are less known, although a new Co(III)sulfathiazole complex have 
been reported as cytotoxic compound without genotoxic effects [56].
In recent years, lanthanum (III) complexes are emerging as promising agents 
due to their more physiological activities and lower toxicities after coordination 
with ligands. The main mechanism of action associated is the interaction with DNA 
by intercalation mode. Likewise, these compounds are useful as clinical biomark-
ers for early diagnosis of the presence of prostate cancer. One of the most relevant 
lanthanum (III) derivative is 2,3-dihydro-1H-indolo[2,3-b]phenazin-4-(5H)-
ylidene)benzothiazole-2-amine (compound 20 in Figure 5) that showed excellent 
anticancer activity in PC-3 cells [57].
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Another relevant option is the gold(I) compounds that can act as prodrugs. 
Thus, 2-mercapto thiazoline as ligand by reaction with K[Au(CN)2] resulted in the 
nitrogen-coordinated complex [NCAu(N-mtz)]. On the other hand, reaction with 
[(Ph3P)AuCl] yielded the sulfur-coordinated complex [(Ph3P)Au(S-mtz)]. Both 
of them inhibited the growth of tumorigenic cell lines such as the human ovarian 
carcinoma (A2780), human colon carcinoma (HCT116), and human breast adeno-
carcinoma (MCF7) [58].
Finally, another strategy to design new complexes as antitumoral agents is the 
combination of anti-inflammatory derivatives with metals. In this approach, the 
1,2-benzothiazines nuclei, which are present in meloxicam and piroxicam, were 
complexed with ruthenium and osmium to obtain new derivatives with potent 
activity against cancer cell lines [59].
6. Peptidic thiazoles
Thiazoles and thiazolines are quite common motifs present in peptides isolated 
from natural sources, many of them known for having biological activity, typi-
cally antibacterial. These peptides are biosynthesized from nonribosomal peptide 
synthase (NRPS) or ribosomally produced and post-translationally modified. Both 
processes involve cyclodehydrations of cysteine residues to yield thiazolines and 
subsequent dehydrogenations to give thiazoles [60]. In this context, marine organ-
ism (cyanobacteria, fungi, sponges, tunicates, ascidians, etc.) provide an endless 
source of new structures with biological potential, cancer included [61]. Many 
isolated thiazole-containing peptides from nature have anticancer properties per se, 
but more efforts are continuously needed by scientific community to enhance and 
modulate its anticancer activity through structure modifications. Recent develop-
ments in this area are included here and listed by its cyclic/acyclic nature.
6.1 Linear peptides
Cyanobacteria-derived bisebromoamide was isolated and tested against HeLa S3 
cells, showing a very low IC50 [62]. It was also shown to induce apoptosis through 
ERK and mTOR inhibition in renal carcinoma cell lines [63]. A modification of cen-
tral thiazoline of bisebromoamide by a thiazole and alanine scanning [64] provided 
new analogs, getting insights in the structural dependence of the cytotoxicity. Four 
analogs showed nanomolar cytotoxicity activity against human colon tumor cell 
line HCT116.
P-glycoprotein (P-gp, multidrug resistance protein 1) is overexpressed in 
patients suffering from chemotherapy resistance. In this sense, cyclic and acyclic 
(S)-valine-derived thiazole peptide dimers, trimers, and tetramers were found to 
be potent P-gp efflux transport inhibitors [65]. Based on this hit, further derivatiza-
tion led to peptidomimetic TTT-28 (Figure 6), which was found to be a potent 
P-gp transport inhibitor and superior to parent compound in reversal of resistance 
to placitaxel in SW620/Ad300 and HEK/ABCB1 cell lines [66]. In vivo study [67] 
showed TTT-28 enhanced intratumoral concentration of placitaxel, inhibiting the 
growth of ABCB1 overexpressing tumors. Additional extensive derivatizations of 
TTT-28 in terminal groups and central thiazole building block side chain helped to 
understand the drug/substrate interactions with P-gp [68]. Modifications on these 
sites led to divergent effects in ATPase efflux pump, from initial stimulation in 
TTT-28 to inhibition.
Polyamides based on 2 and 3 repeating units of 2-aminothiazole-4-carboxylic 
acid were synthetized [69] and proved to bind selectively to c-MYC quadruplex 
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over other G-quadruplex and duplex DNA and therefore inhibiting c-MYC onco-
gene transcription. Antiproliferative activity of the tripeptide was found in HeLa 
cells, caused by apoptotic pathway.
Thiazole scaffold is also present in short peptides known for inhibiting tubulin 
polymerization. Dolastatin 10 was firstly isolated from Dolabella auricularia and is 
composed of five unnatural amino acids with a thiazole ring in C-terminal (Figure 6). 
It was demonstrated as very potent in cell proliferation assays (IC50 < 5.0 nM), but 
due to its high toxicity at maximum tolerated dose, new analogs have been devel-
oped. N-Terminal modified dolastatin analog (PF-06380101) bearing a quaternary 
amino acid was found to have improved potency and suitable ADME properties for 
antibody-drug conjugates [70]. Modified dolastatins at thiazole moiety by addition 
of new functionalities as alcohols, amines, and thiols have also been reported [71]. 
These analogs also showed low IC50 for several cancerous cell lines.
Another thiazole-containing peptides targeting to tubulin polymerization 
are the tubulysins (Figure 6), isolated first from myxobacteria. Great number of 
modifications have been attempted to date, and numerous SAR studies have shed 
light into tubulysin mode of action (for a review, see ref. [72]).
In this context, a pretubulysin (tubulysin biosynthetic precursors) lacking of C11 
acetate and bearing a methyl group at N14 showed efficacy against various in vivo 
metastatic bladder, breast, and lung cancer models [73]. New tubulysin derivative 
KEMTUB10 with a N14-benzyl-Tuv and 4-fluorophenyl moiety in Tup exhibited 
activity in the picomolar range in the main breast cancer cell lines [74]. It blocks 
cells in G2/M phase of the cell cycle and stimulates apoptosis. In line with these 
results, attachment of alkyl groups at mentioned Tuv N14 as benzyl, 4- 
fluorobenzyl, and cyclopropylmethyl in tubulysins also led to superpotent cytotoxic 
activity [75]. More Tuv modifications have been reported, like the incorporation 
of tetrahydropyranyl ring by Diels-Alder reaction for conformational restriction 
of tubulysin [76], but rigidification seemed to affect negatively to polymerization 
inhibition. Systematic derivatization by substitution of each subunit of tubulysin 
by diverse moieties, including three-dimensional structural motifs such as cubane 
and [1.1.1]-bicyclopentane, was reported [77]. A profound structure-activity study 
indicated that thiazole in Tuv unit cannot be substituted by 3D motifs but can be 
replaced by aromatics such as pyridine without significant loss of activity.
Figure 6. 
Thiazole/thiazoline containing peptides and peptidomimetics with anticancer activity.
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One objective for researchers working with tubulysins is the improvement of 
their therapeutic efficacy by the targeted cancer therapy as antibody-drug conjuga-
tion (ADC) or small molecule drug conjugates (SMDC), acting the tubulysins as 
payloads. This represents a very powerful tool, which is already being applied to 
all class of tubulin inhibitors [78]. Tubulysin warheads are therefore being used 
in ADC; one of them (AZ13599185) is in phase I clinical trials targeting HER2 
receptors, involved in breast cancer development [79]. Following this trend, the 
modifications of tubulysins for an easier linking to conjugates is a new goal. New 
derivatizations at C-terminal Tup showed broad tolerance with no loss of activity, 
enabling more opportunities to conjugate to biomolecules and receptor ligands 
[80]. Another issue that arose during ADC conjugation of tubulysins to trastu-
zumab is the metabolism of C11 acetate in vivo, inactivating the payload [81, 82]. 
The problem was solved replacing the acetate ester by a more inert functionality to 
esterases like carbamates, retaining the activity. Tubulysin warheads have also been 
applied in a SMDC strategy in conjugation with folic acid to address folate receptor 
(FR), expressed in many cancers [83]. The EC1456 conjugate was tested in mice 
bearing FR-positive xenografts leading to curation of 100%. Results against human 
vintafolide-resistant xenografts were also positive.
6.2 Cyclic peptides
Cyclic depsipeptide largazole was discovered from cyanobacteria Symploca sp. 
[84], and its distinctive structural feature is the presence of a thiazole fused linearly 
to a 4-methylthiazoline and a labile thioester (Figure 6). Largazole possesses great 
activity as inhibitor of class I histone deacetylase (HDAC) metalloenzymes [85], 
a promising target for chemotherapy. Many largazole structure-activity relation-
ship studies have been reported. Among multiple sites of modification performed, 
thiazole-thiazoline fragment located in the macrocycle seems to be the most 
promising to achieve more potent and selective analogues. Substitution of thiazole 
by pyridyl residues and depsipeptide framework alteration to peptide isostere led to 
equipotent largazole analogues but with improved selectivity for different HDACs 
[86]. The replacement of thiazole and thiazoline by bipyridyl fragments led to 
derivatives with a similar activity of largazole, but with an improved selectivity for 
class I HDAC [87].
Largazole inhibition of HDAC is actually attained by largazole thiol derived 
from thioester hydrolysis. The thiol forms a thiolate-Zn2+ complex [88], a critical 
binding for the activity, since substitution by other poorer Zn-binding groups 
correlated to less HDAC inhibition and lower cytotoxicity [89]. The octanoyl side 
chain on the thioester allows good cell permeability. Thus, modifications can be 
made for a better membrane permeability and thiol liberation inside the cell. In 
this sense, controlled release of largazole thiol from an isobutylene-caged largazole 
thiol derivative, which possesses a high permeability, has been achieved by UV light 
photoactivation of a thiol-ene triggering reaction [90].
Cyclic thiazole- and oxazoline-containing octapeptides and patellamides, 
isolated from marine tunicates, have also been an object of modification. It has been 
shown that changes in the position of thiazoles and oxazolines in ascidiacyclamide 
can influence their cytotoxic activity, obtaining inactive derivatives and 10 times 
more active compounds depending on the conformations attained [91].
Apratoxin- and thiazoline-containing depsipeptides are known potent cyto-
toxins isolated from marine cyanobacteria. Apratoxins are known for being potent 
anticancer agents and co-translational translocation inhibitors. Different deriva-
tives have been synthetized, involving thiazoline stereogenic configuration change 
at C30 and substitution in C34 [92] (Figure 6). A new derivative, apratoxin S10 with 
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(R)-C30 thiazoline and the addition of a methyl group at C34, shows potent in vitro 
angiogenesis and vascularized tumor cell growth inhibition [93]. It showed antipan-
creatic cancer activity, including in orthotopic pancreatic patient-derived xenograft 
mouse model [94]. Other derivatizations consisting of thiazoline substitution 
by piperidinecarboxylic acid moiety have been developed [95]. Apratoxins M16 
showed comparable cytotoxicity to apratoxin A in HCT116 cancerous cells.
7. Conclusion
Incorporation of thiazole ring into different molecules have demonstrated to be 
a novel and promising approach to design more potent and safer antitumor drugs. 
The results of this chapter might help to enlighten other researchers to better design 
bioactive molecules. This thiazole ring can be incorporated as part of mono- or 
fused-cycles, metal complexes, or as a part of peptides. In many of these cases, 
the deletion of thiazole ring entails the loss of the bioactivity pointing out the 
importance of this ring for the anticancer activity. Thus, we consider this class of 
compounds and excellent starting point to achieve future drug candidates to treat 
cancer.
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